Clinical Trial Update: Trial of a New Formulation of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease

View source ↗

Summary

Completed clinical trial evaluating a new formulation of ferric citrate (KRX-0502) for hyperphosphatemia in patients with end-stage renal disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• Ferric citrate (ferric citrate)

Snippet

Sponsor: Keryx Biopharmaceuticals | Conditions: Hyperphosphatemia, End-stage Renal Disease | Status: COMPLETED | Results posted: 2014-11-18